Accenture: A Greener And Attractive Leader In Everything They Do
Summary: Despite the economic slowdown, ACN managed to generate outstanding growth in both its topline and EPS.It also...
Month: September 2022
Abiomed: Correction Offers Good Buying Opportunity
Summary: Abiomed’s Impella range of micro heart pumps enjoy rising demand in the marketplace.The company’s OXY-1 System...
Eli Lilly: Valuation Feels Impossibly High – Don’t Board This Hype Train
Summary: Eli Lilly's share price performance over the past 5 years is +290%. The rest of the US Big Pharma sector averages...
Investors In Quantum Computing Inc. Should Be Very Cautious
Summary: Quantum Computing (QCI) bills itself as a “full-stack quantum software and hardware company".QCI's Marquee...
Algonquin Power Is The Only Water Utility I Own
Summary: After supporting the industry since the late 1990s, I have done an about-face and currently avoid the water...
Medtronic: Prefer U.S. Treasury Bonds
Summary: Medtronic entered a bear market and has fallen more than the S&P 500 since the last quarter of 2021.Since I see...
American Airlines Vs. Southwest Airlines: The Battle Of Balance Sheets
Summary: The airline industry is massively undervalued and many investors start to take a look at which company could be...
Avoid Arrival: It Is Just Getting Darker
Summary: Positive news in the early summer gave false hope in Arrival’s performance. It was dashed by reality during Q2...
Merck: A Gem In A Period Of Economic And Geopolitical Uncertainties
Summary: Merck's operating income was $5,293 million in Q2 2022, up 37.5% year-over-year.Merck's key medicines have...
Abercrombie & Fitch Q2 Review: Lay Off
Summary: Abercrombie & Fitch Co. recently reported Q2 earnings that missed on both the top and bottom line.The company, yet...